Therapeutic hub
Endocrine Peptides
Growth hormone axis peptides, releasing hormones, and secretagogues — an area where approved indications are narrow and off-label promotion is common.
Regulatory picture
A small number of narrow approvals; most marketed compounds are unapproved.
What this area covers
Endocrine peptides modulate hormone axes — most visibly the hypothalamic-pituitary growth hormone axis, but also thyroid, adrenal, and reproductive signalling.
Approvals in this space tend to be tightly scoped to specific deficiency states or defined patient populations, often with monitoring requirements.
Fig. 02 / Molecular pathwayWhy anti-ageing framing is not supported
Raising growth hormone or IGF-1 concentrations changes a biomarker. It does not, on current evidence, establish improved long-term health outcomes in people without a diagnosed deficiency, and sustained elevation carries theoretical risks that have not been resolved in long-term studies.
Monitoring considerations discussed in the literature
Where these agents are used in approved contexts, clinical monitoring typically includes glucose metabolism, IGF-1 levels, and symptom review. This is described here to explain clinical practice, not as guidance for use.
Fig. 03 / Evidence landscapeProfiles in this area
Tesamorelin
Endocrine · Endocrine / metabolic
A growth-hormone-releasing hormone analogue approved for a narrow indication: reduction of excess abdominal fat in people with HIV-associated lipodystrophy.
Ipamorelin
Endocrine · Endocrine (proposed)
A selective growth hormone secretagogue studied in early clinical work and later discontinued. It is not an approved medicine and is widely sold in unapproved channels.
CJC-1295
Endocrine · Endocrine (proposed)
A long-acting GHRH analogue investigated in early trials and never approved. Commonly marketed in unapproved channels alongside other secretagogues.
Editorial disclaimer
This site is educational and does not provide medical advice, dosing protocols, or treatment recommendations. Regulatory status and evidence strength differ sharply between compounds. A “research use only” label does not indicate that a product is appropriate for human use. Decisions about medicines belong with a qualified clinician.